A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain
Status:
Not yet recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate
efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in
adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP). The primary
objective of the study is to assess the efficacy of GSK3858279 in participants with DPNP who
have been unable to sufficiently manage their pain.